Corbus Pharmaceuticals CRB-701 Phase 3 Head and Neck Cancer Trial Starts September 20, 2026: Oropharyngeal Carcinoma Study Design

Corbus Pharmaceuticals Holdings (CRBP) has a Phase 3 oncology trial reaching its expected start date of September 20, 2026, according to trial registration data tracked by BioSniper since September 2, 2026. The study evaluates CRB-701 against investigator's-choice chemotherapy in patients with recurrent or metastatic oropharyngeal squamous cell carcinoma previously treated with platinum chemotherapy and a PD-(L)1 inhibitor. For a company with a market capitalization of roughly $205 million in our snapshot, a Phase 3 start is the kind of event that dominates the catalyst calendar — and this one arrives almost exactly one year after an advisory committee record for the same drug candidate.

The event

The trial is registered in our catalyst dataset as:

"A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor"

The expected start date — September 20, 2026 — is recorded with "exact" date confidence. As of publication, no actual start is recorded in our data.

What's verified

• Company: Corbus Pharmaceuticals Holdings, Inc., ticker CRBP, active listing status.
• Event type: Phase 3 trial start.
• Expected date: September 20, 2026, "exact" confidence.
• First tracked: September 2, 2026.
• Design elements from the registered title: randomized; 2-arm; CRB-701 versus investigator's choice; the investigator's-choice options named as capecitabine, cetuximab, or docetaxel; population recurrent or metastatic oropharyngeal squamous cell carcinoma; prior therapy platinum-based chemotherapy and a PD-(L)1 inhibitor; endpoints named as efficacy and safety.
• Company scale: Market capitalization of $204,920,992 in our snapshot — a small-cap name where single catalysts carry outsized weight relative to the AZNs of the world.

What our 13F data shows

Our institutional holdings snapshot for Corbus (as of quarter-end March 31, 2026) records a single institution with a 13F-filed position: UBS Group AG, holding 38,638 shares valued at $362,811. Our data shows 6 quarterly trend points for the name. A one-institution 13F footprint at this size is not unusual for a micro-cap and is reported here exactly as the filings show.

What remains unknown

• Enrollment size: UNKNOWN in our data.
• Mechanism or target for CRB-701: our event record does not include target information, and we will not describe the molecule beyond the registered title.
• Actual start date and readout timing: not recorded.
• AdCom outcome: our tracker holds an advisory committee record for CRB-701 dated September 16, 2025 (see below), but its outcome field is empty in our data.

Platform context: the CRB-701 record and a three-program company

Our calendar holds exactly four catalyst records for Corbus, and the CRB-701 pair stands out:

• AdCom: CRB-701 — September 16, 2025. An FDA advisory committee record for the same candidate, almost exactly one year before this trial's expected start. Our outcome field for that AdCom is empty — we know the committee meeting was tracked, not what transpired.
• CRB-913 — December 4, 2025. A Phase 1b randomized, double-blind, placebo-controlled dose-range-finding study in participants with obesity, with efficacy, safety, and pharmacokinetics endpoints and a single-cohort open-label pharmacokinetic lead-in.
• CRB-601 — December 4, 2024. A Phase 1/2 study in patients with advanced solid tumors; the registered title describes it as a monoclonal antibody against integrin αvβ8.

Three named programs — CRB-701 in head and neck cancer, CRB-913 in obesity, CRB-601 in advanced solid tumors — and a Phase 3 start on September 20, 2026 make CRB-701 unambiguously the company's lead catalyst story in our data. The full four-record calendar spans less than two years, from the CRB-601 Phase 1/2 registration (December 4, 2024) through the CRB-913 obesity Phase 1b and the CRB-701 advisory committee record (both dated December 4, 2025 and September 16, 2025 respectively in our tracker) to this Phase 3 start — a compact, legible pipeline history for a company at this market size.

Why the comparator design matters for readers

The registered comparator arm — investigator's choice of capecitabine, cetuximab, or docetaxel — is the standard pragmatic design for platinum- and checkpoint-experienced recurrent or metastatic head and neck cancer, where no single standard second-line-plus regimen dominates. Our data verifies the design as registered; how the trial executes and what it shows are unknowns we will track, not predict.

How to track it

• Corbus Pharmaceuticals company page — full catalyst calendar: https://biosniper.co/company/CRBP
• This trial-start event page: https://biosniper.co/calendar/event/5788737

Bottom line

A registered Phase 3 start for CRB-701 versus investigator's-choice therapy in platinum- and PD-(L)1-pretreated oropharyngeal squamous cell carcinoma lands on September 20, 2026, for a $205 million-market-cap company whose entire tracked history is three programs. The same candidate has an advisory committee record dated September 16, 2025 with an empty outcome field in our data. Enrollment size, mechanism, and results are unknowns; the design skeleton above is exactly what the registration states.